Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01610687
Other study ID # GWMS0001 EXT
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 2001
Est. completion date February 2005

Study information

Verified date December 2022
Source Jazz Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.


Description:

Patients who participated in the placebo controlled phase of this study and opted to continue receiving open label GW-1000-02 entered the follow-on extension of the study and completed symptom assessments to determine whether they were continuing to receive clinical benefit from GW-1000-02.


Recruitment information / eligibility

Status Completed
Enrollment 137
Est. completion date February 2005
Est. primary completion date February 2005
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged at least 18 years. - Multiple Sclerosis of any type. - Stable Multiple Sclerosis symptomatology during the four weeks before study entry. - Symptoms of the required severity (>50 mm on a 100 mm Visual Analogue Scale severity scale) in least one of the specified impairment categories; spasticity, muscle spasms, disturbed bladder control, neuropathic pain, limb tremor. - A stable medication regime during the four weeks before study entry. - Willing to abstain from cannabis or cannabinoids for at least seven days before study entry, and during the study. - Agreed either to use effective contraception during the study and for three months thereafter, or had been surgically sterilised or, if female, were post-menopausal. - Clinically acceptable laboratory results for pre-study screening. - Willing and able to undertake and comply with all study requirements. - Willing and able to read, consider and understand the subject information and consent form and give written informed consent. Subjects unable to read or to sign the document procedures were treated as detailed in the Declaration of Helsinki. - Willing for their general practitioner, and consultant if appropriate, to be informed of study participation. - Willing for their name to be notified to Home Office for participation in the study. Exclusion Criteria: - Known or strongly suspected to be abusing drugs, including alcohol. - Not prepared to abstain from cannabis or cannabinoids during the study. - Current or past addiction to cannabis. - Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness. - History of any type of schizophrenia, any other psychotic illness, or other significant psychiatric illness or personality disorder other than depression associated with chronic illness. - Received any drug containing levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®). - Serious cardiovascular disorder including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia. - Significant renal or hepatic impairment as shown in medical history or indicated by laboratory results. - History of epilepsy. - Terminal illness or other condition in which placebo medication would be inappropriate. - Pregnant, lactating or at risk of pregnancy. - Participated in any other clinical research study during the 12 weeks before study entry. - Planned hospital admission between study entry and Visit 6. - Planned travel outside the UK between study entry and Visit 6.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GW-1000-02
Contained THC and CBD as extract of Cannabis sativa L. Each 100 µl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.

Locations

Country Name City State
United Kingdom Rivermead Rehabilitation Centre Oxford

Sponsors (1)

Lead Sponsor Collaborator
Jazz Pharmaceuticals

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006 Oct;12(5):639-45. doi: 10.1177/1352458505070618. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events as a Measure of Patient Safety The number of patients who experienced an adverse event during the course of this extension study is presented up to1206 days
Secondary Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment A categorical summary was produced of the mean number of sprays per day during the last six days of treatment, and the mean number of sprays was rounded to the nearest whole number for categorisation. up to 1206 days
Secondary Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18. Intoxication levels were recorded on a Visual Analogue Scale, where 0 equals 'no intoxication' and 10 equals 'extreme intoxication'. A decrease in score indicates an improvement in intoxication levels. 18 weeks
Secondary Investigator Assessed Global Severity Score at Week 18 The investigator rated the global severity of the subject's primary condition since entry into the study using a five-point verbal rating scale-5: 1=much worse, 2=worse, 3=no change, 4=better, 5=much better. The number of patients which were considered better or much better (scores 4 and 5) at week 18 of the study better is presented. week 18
Secondary Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18 A clinical assessment of pain was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no pain and 100 = worst possible pain. A decrease in score indicates an improvement. week 18
Secondary Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18 A clinical assessment of spasticity was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no spasticity and 100 = worst possible spasticity. A decrease in score indicates an improvement. week 18
Secondary Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18 A clinical assessment of tremor was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no tremor and 100 = worst possible tremor. A decrease in score indicates an improvement. week 18
Secondary Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18 A clinical assessment of bladder problems was made at each study visit using a 100 mm Visual Analogue Scale, where 0 = no bladder problems and 100 = worst possible bladder problems. A decrease in score indicates an improvement. 18 weeks
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4